Zydus reveals positive data from EVIDENCES IV phase 2 clinical trial
Category: #health  By Mateen Dalal  Date: 2019-10-07
  • share
  • Twitter
  • Facebook
  • LinkedIn

Zydus reveals positive data from EVIDENCES IV phase 2 clinical trial

Non-alcoholic Steatohepatitis (NASH) is a progressive disease which can ultimately lead to cirrhosis and liver failure. Liver transplantation is the only treatment for managing advanced cirrhosis with liver failure. There are currently no U.S. Food and Drug Administration (USFDA) approved treatments for NASH cirrhosis. Thus, researchers are coming up new with treatments that can treat this disease effectively.

Zydus Cadila is a global pharmaceutical company that has reportedly announced encouraging results from the EVIDENCES IV clinical trial of Saroglitazar Magnesium, an investigational molecule in U.S., undergoing clinical evaluation for treatment of liver diseases like NAFLD (Non-alcoholic fatty liver disease) with PCOS (polycystic ovary syndrome), Primary Biliary Cholangitis (PBC) and Nonalcoholic Steatohepatitis (NASH).

According to reports, Saroglitazar Magnesium achieved the primary endpoint in the EVIDENCES IV clinical trial, a double-blind, placebo-controlled, and randomized study that registered 106 patients with NAFLD comprising NASH across 20 U.S. based clinical sites.

Reportedly, for 16 Weeks; patients were randomly assigned in a ratio of 1:1:1:1 to receive the dose of 1mg, 2mg or 4mg or a matching placebo once in a day before breakfast in the morning.

Speaking on the trial, Prof. Naga P. Chalasani, MD and Associate Dean for Clinical Research and Director, Division of Gastroenterology & Hepatology, Indiana University School of Medicine, said that an authority in the areas of NAFLD and drug-induced liver injury was the lead Principal Investigator of the EVIDENCES IV trial.

Chalasani claims that 4mg dose of Saroglitazar had considerably improved liver biochemistries, insulin resistance, hepatic steatosis, dyslipidemia with zero weight gain or fluid retention. He added that these results were quite promising as there is a dire need for a drug that improves not only liver disease treatment but also is important co-morbidities such as dyslipidemia and insulin resistance.

Reliable sources cite that the study achieved primary endpoint in the EVIDENCES IV clinical trial when there was a percentage change in serum ALT levels at week 16, from baseline, in the Saroglitazar Magnesium groups comparing to the placebo group.

Source Credit - https://zyduscadila.com/public/pdf/pressrelease/Zydus_NASH_US_Press_Release.pdf

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Telenor to sell stake in Myanmar's Wave Money for $53 Mn to Yoma
Telenor to sell stake in Myanmar's Wave Money for $53 Mn to Yoma
By Mateen Dalal

Telenor Group, an international provider of tele, data and media communication services, has reportedly agreed to sell its 51% stake in Myanmar's Wave Money, a provider of digital payment service, for $53 million to Yoma MFS Holdings, a subsidiar...

Alkem to launch state-of-the-art technology to treat DFU in India
Alkem to launch state-of-the-art technology to treat DFU in India
By Mateen Dalal

Alkem Laboratories Ltd. (Alkem), an Indian multinational pharmaceutical company, has reportedly launched a unique patented technology for the treatment of Diabetic Foot Ulcer (DFU) in India. The solution would be based on an innovative technology of...

Bank of America unveils new drive-thru ATM; shuts another in Bethlehem
Bank of America unveils new drive-thru ATM; shuts another in Bethlehem
By Mateen Dalal

According to Andy Aldridge, Bank of America Spokesperson, the financial institutiThe Bank of America Corporation, an American multinational investment bank and financial services, has now opened up a new place for clients in North Bethlehem who are l...